Anti-H5N1 immunoglobulin - Fabentech

Drug Profile

Anti-H5N1 immunoglobulin - Fabentech

Alternative Names: Fabenflu; FBF001

Latest Information Update: 14 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Fabentech
  • Developer Fab entech
  • Class Antivirals; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Influenza A virus H5N1 subtype
  • New Molecular Entity No

Highest Development Phases

  • Suspended Influenza A virus H5N1 subtype

Most Recent Events

  • 14 Jul 2017 Suspended - Phase-I for Influenza-A virus H5N1 subtype (In volunteers) in Singapore (Parenteral) (Fabentech communication, July 2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(In volunteers) in Singapore (Parenteral, Injection)
  • 12 Oct 2012 Phase-I clinical trials in Influenza-A virus H5N1 subtype (In volunteers) in Singapore (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top